IBD Market Snapshot: Changes Ahead, But Current Biologics Are Formidable Competitors
Zeposia Adds A Second Oral Advanced Therapy
The ulcerative colitis and Crohn’s disease landscapes may shift soon but new drugs will compete with entrenched blockbusters, including Humira, Stelara and Entyvio, with biosimilars on the way.
